Phase 1b Open-label, Dose-Identification Study of XPro1595 in Patients with Mild to Moderate Alzheimer's Disease with Elevated high sensitivity C-reactive protein in Blood.
- O'Brien, Terence (Primary Chief Investigator (PCI))
- Burn, Katherine (Project Manager)
- Woodward, Michael Clifford (Chief Investigator (CI))
- Lai, Rosalyn (Chief Investigator (CI))
- Clarnette, Roger (Chief Investigator (CI))
- Brodtmann, Amy (Chief Investigator (CI))
- Nestor, Peter J (Chief Investigator (CI))
Project: Research